– USA, MA – Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Brian Levy, O.D., M.Sc., has joined Ocata’s Board of Directors. Most recently, Dr. Levy served as Chief Medical Officer of Aerie Pharmaceuticals, Inc.
“Brian has been a widely regarded leader in the pharmaceutical industry for more than two decades, including fifteen years at Bausch + Lomb where he was the Chief Medical Officer and he brings significant drug development and commercialization experience, particularly in ophthalmic products, to Ocata” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “We are pleased that Brian is joining our board to provide his expertise and guidance as we enter our next phase of advanced clinical trials for Dry AMD and Stargardt’s disease with our RPE therapy.”
In addition to Aerie Pharmaceuticals, Dr. Levy served as Chief Scientific Officer at Nexis Vision and as Chief Operating Officer at Danube Pharmaceuticals, Inc., both venture-backed companies developing products in ophthalmology. Prior to this, Dr. Levy served in senior roles at Bausch + Lomb, Inc., first as Vice President of Research & Development, and ultimately as Chief Medical Officer. Prior to joining Bausch + Lomb, Inc., Dr. Levy served as an Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco and was in private clinical practice. He currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester’s School of Medicine.
“I am delighted to join Ocata’s board of directors at this exciting time as the company initiates the next stage of development for its lead RPE programs and begins to advance its pre-clinical pipeline,” commented Dr. Levy. “I look forward to working closely with the board and the management team at Ocata applying its world class regenerative medicine platform to deliver novel therapeutics for many patients with disease states like dry AMD and Stargardt’s, where there are significant unmet medical needs and where no effective products currently exist.”
Dr. Levy received his Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received an MS degree.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
